United States · Bill · HR
H.R. 8177 (116th)
RAISE Act
Introduced
4 September 2020
Last action
—
Status
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsors
—
Subjects
Discovery layer
Source updated
3 January 2025
Summary
Renal Anemia Innovation Support and Expansion Act or the RAISE Act This bill allows coverage of prescription vitamin and mineral products under the Medicare prescription drug benefit if the products are administered orally and are used to treat iron deficiency anemia in individuals who have chronic kidney disease.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 4 September 2020
Introduced in House (PDF)
Introduced in House · EN · 4 September 2020
Introduced in House
summary · EN · 4 September 2020
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/116th-congress/house-bill/8177
- Open data entity: https://api.congress.gov/v3/bill/116/hr/8177